{"id":"W2979946483","doi":"10.1182/blood.v118.21.3842.3842","title":"Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Placebo; Quality of life (healthcare); Internal medicine; Clinical trial; Bone pain; Phases of clinical research; Randomized controlled trial; Anemia; Adverse effect; Surgery; Gastroenterology; Physical therapy; Bone marrow; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823534,0.001197147,0.002700023,0.000337179,0.0003932939,0.0007402255,0.0006374873,0.001440439,0.004108327],"category_scores_gemma":[0.00159449,0.0006873017,0.001740282,0.000261923,0.0008526369,0.0007250524,0.0003940452,0.001868828,0.0004815845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006019243,"about_ca_system_score_gemma":0.0007748027,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003987151,"about_ca_topic_score_gemma":0.001105316,"domain_scores_codex":[0.9992602,0.0004051502,0.00007590256,0.0001193241,0.00005340722,0.00008601239],"domain_scores_gemma":[0.9987125,0.0003749419,0.0004063486,0.00006896746,0.00007007332,0.0003670494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9813265,0.005307353,0.001660504,0.0003220783,0.0006079736,0.00001679588,0.0000273673,0.0001885202,0.002701063,0.00002705515,0.0002620689,0.007552638],"study_design_scores_gemma":[0.8286504,0.1613182,0.007772591,0.0000291074,0.0006691325,0.00003377892,0.00001717368,0.0004969846,0.0006705174,0.00005069927,0.0002726766,0.00001861333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959348,0.001724877,0.0001615333,0.0001572578,0.0001004925,0.0009750303,0.0003770953,0.00003094638,0.0005379219],"genre_scores_gemma":[0.9957456,0.0005699066,0.0005383624,0.0003211407,0.0002506304,0.00147006,0.0004962473,0.000004845492,0.0006032292],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004108327,"threshold_uncertainty_score":0.01374376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05957677631218394,"score_gpt":0.2992773968094112,"score_spread":0.2397006204972272,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}